[A22-60] Abrocitinib (atopic dermatitis) - Addendum to Commission A22-06
Last updated 07.07.2022
Project no.:
A22-60
Commission:
Commission awarded on 24.05.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Indication:
Moderate to severe atopic dermatitis in adults who are candidates for systemic treatment
Result of dossier assessment:
After addendum:
- < 40 years: indication of considerable added benefit
- ≥ 40 years: indication of major added benefit
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A22-06 | Abrocitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
07-07-2022 A G-BA decision was published.